Decoy Therapeutics Shares Outstanding History (DCOY)
Decoy Therapeutics reported 96,125.172 shares outstanding at the end of fiscal 2024.
View full Decoy Therapeutics company overviewDecoy Therapeutics annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2024 | 2024-12-31 | 96,125.172 | 63,288.495 | +192.74% |
| 2023 | 2023-12-31 | 32,836.677 | 14,028.119 | +74.58% |
| 2022 | 2022-12-31 | 18,808.558 | 3,721.076 | +24.66% |
| 2021 | 2021-12-31 | 15,087.482 | 7,147.332 | +90.02% |
| 2020 | 2020-12-31 | 7,940.15 | 6,435.674 | +427.77% |
| 2019 | 2019-12-31 | 1,504.477 | 826.55 | +121.92% |
| 2018 | 2018-12-31 | 677.926 | −5,257.432 | −88.58% |
| 2017 | 2017-12-31 | 5,935.359 | 341.297 | +6.10% |
| 2016 | 2016-12-31 | 5,594.062 | 344.232 | +6.56% |
| 2015 | 2015-12-31 | 5,249.83 | 4,510.89 | +610.45% |
| 2014 | 2014-12-31 | 738.94 | — | — |
Decoy Therapeutics quarterly shares outstanding
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 531,968 | 390,078.024 | +274.92% |
| Q1 2026 | 2026-03-31 | 531,968 | 393,109.339 | +283.10% |
| Q4 2025 | 2025-12-31 | 8,006 | −88,119.172 | −91.67% |
| Q3 2025 | 2025-09-30 | 944,491 | 848,365.828 | +882.56% |
| Q2 2025 | 2025-06-30 | 141,889.976 | 99,123.47 | +231.78% |
| Q1 2025 | 2025-03-31 | 138,858.661 | 102,887.076 | +286.02% |
| Q4 2024 | 2024-12-31 | 96,125.172 | 63,288.487 | +192.74% |
| Q3 2024 | 2024-09-30 | 96,125.172 | 63,288.487 | +192.74% |
| Q2 2024 | 2024-06-30 | 42,766.506 | 14,818.631 | +53.02% |
| Q1 2024 | 2024-03-31 | 35,971.585 | 15,392.159 | +74.79% |
| Q4 2023 | 2023-12-31 | 32,836.685 | 14,028.127 | +74.58% |
| Q3 2023 | 2023-09-30 | 32,836.685 | 32,086.52 | +4277.26% |
| Q2 2023 | 2023-06-30 | 27,947.875 | 9,233.108 | +49.34% |
| Q1 2023 | 2023-03-31 | 20,579.426 | 5,005.912 | +32.14% |
| Q4 2022 | 2022-12-31 | 18,808.558 | 3,720.415 | +24.66% |
| Q3 2022 | 2022-09-30 | 750.165 | −14,314.875 | −95.02% |
| Q2 2022 | 2022-06-30 | 18,714.767 | 3,781.039 | +25.32% |
| Q1 2022 | 2022-03-31 | 15,573.514 | 654.616 | +4.39% |
| Q4 2021 | 2021-12-31 | 15,088.143 | 7,147.993 | +90.02% |
| Q3 2021 | 2021-09-30 | 15,065.04 | 8,455.433 | +127.93% |
| Q2 2021 | 2021-06-30 | 14,933.728 | 10,051.952 | +205.91% |
| Q1 2021 | 2021-03-31 | 14,918.898 | 10,368.065 | +227.83% |
| Q4 2020 | 2020-12-31 | 7,940.15 | 6,435.674 | +427.77% |
| Q3 2020 | 2020-09-30 | 6,609.607 | 5,356.92 | +427.63% |
| Q2 2020 | 2020-06-30 | 4,881.776 | −1,144.116 | −18.99% |
| Q1 2020 | 2020-03-31 | 4,550.833 | −1,474.85 | −24.48% |
| Q4 2019 | 2019-12-31 | 1,504.477 | −4,520.999 | −75.03% |
| Q3 2019 | 2019-09-30 | 1,252.687 | −4,772.579 | −79.21% |
| Q2 2019 | 2019-06-30 | 6,025.892 | 0.834 | +0.01% |
| Q1 2019 | 2019-03-31 | 6,025.684 | 29.07 | +0.48% |
| Q4 2018 | 2018-12-31 | 6,025.475 | 90.116 | +1.52% |
| Q3 2018 | 2018-09-30 | 6,025.267 | 175.218 | +3.00% |
| Q2 2018 | 2018-06-30 | 6,025.058 | 260.202 | +4.51% |
| Q1 2018 | 2018-03-31 | 5,996.614 | 317.36 | +5.59% |
| Q4 2017 | 2017-12-31 | 5,935.359 | 341.297 | +6.10% |
| Q3 2017 | 2017-09-30 | 5,850.049 | 341.181 | +6.19% |
| Q2 2017 | 2017-06-30 | 5,764.856 | 341.886 | +6.30% |
| Q1 2017 | 2017-03-31 | 5,679.255 | 341.672 | +6.40% |
| Q4 2016 | 2016-12-31 | 5,594.062 | 344.232 | +6.56% |
| Q3 2016 | 2016-09-30 | 5,508.869 | 356.524 | +6.92% |
| Q2 2016 | 2016-06-30 | 5,422.97 | 356.82 | +7.04% |
| Q1 2016 | 2016-03-31 | 5,337.583 | 357.728 | +7.18% |
| Q4 2015 | 2015-12-31 | 5,249.83 | 5,077.287 | +2942.63% |
| Q3 2015 | 2015-09-30 | 5,152.345 | — | — |
| Q2 2015 | 2015-06-30 | 5,066.15 | — | — |
| Q1 2015 | 2015-03-31 | 4,979.855 | — | — |
| Q4 2014 | 2014-12-31 | 172.542 | — | — |
Decoy Therapeutics shares outstanding trends
Over the last five reported fiscal years, Decoy Therapeutics's shares outstanding moved from 1,504.477 to 96,125.172, a change of 94,620.695. The latest reported quarter, Q2 2026, shows 531,968.
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when SEC-reported stock-split conversion ratios are available. Values remain as reported when no split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Decoy Therapeutics filings at SEC.gov ↗